Skip to main content

I6T-MC-AMAN A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional -Failed and Biologic-Failed Patients with Moderately to Severely Active Colitis - AMAN

NCT03518086

A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional -Failed and Biologic-Failed Patients with Moderately to Severely Active Colitis - AMAN

Associated Conditions

Inflammatory Bowel Disease (IBD)

Principal Investigator

Sponsor

Lilly USA

The main reason for you to take part in this study is not to treat you for your condition but to help in answering the following research question: How mirikizumab, the investigational drug, compares with placebo in helping patients with ulcerative colitis. “Investigational” means that the drug being tested has not been approved for routine clinical use or for the use described in this study by the United States Food and Drug Administration (FDA). The FDA is allowing the use of this drug for research.